
Made-Inside-Body CAR T Cells Clear Mouse Leukemia
Azalea's preclinical in vivo platform still needs human trials before it could reach patients.
For readers in California, this page covers gene editing, drug development, clinical trial results and biotech financings. Reporting follows the companies, research institutions and regulatory decisions shaping the state's life sciences sector.

Azalea's preclinical in vivo platform still needs human trials before it could reach patients.
November 4, 2026
Gene Therapies Could Target Cholesterol RiskScribe's two investigational liver-targeted treatments will be presented in Chicago in November 2026, with human data still early.
November 3, 2026
Prop 38 Would Fund Immunology With $8.4 BillionCalifornia voters decide on November 3, 2026 whether state bonds should finance immunotherapy research that repays itself from research revenue.
November 3, 2026
Gene-Edited Grains Could Fix Their Own NitrogenThe approach is research-stage, with commercial products likely no earlier than the next decade after field testing.
November 2, 2026
Solano Students Gain State-Funded Biomanufacturing PathA $6.55 million CIRM award funds a training pipeline from lab work to industry internships, with outcomes not yet reported.
November 2, 2026
Tribunal Keeps AMT Offset Rule for DrugmakersCalifornia's tax tribunal rejected a bid to overturn a 15-year-old precedent that governs corporate AMT offsets.
November 2, 2026
California Voters to Decide on Research BondsTwo proposed state bonds, totaling over $15 billion, would fund biomedical research if approved at the ballot box in 2026 and 2028.
October 30, 2026
Judge Finalizes $69 Million ChemoCentryx SettlementThe agreement resolves investor claims concerning safety disclosures for a vasculitis treatment developed by the firm.
October 30, 2026
Researchers Develop 3D-Bioprinted Retinal GraftsThe two-year grant supports research into restoring vision for patients with degenerative retinal conditions.
October 27, 2026
Artiva Biotherapeutics Halts AlloNK Cell Therapy TrialsThe company is ending development of its autoimmune cell therapy following two patient deaths in clinical trials.
October 22, 2026
Estrella Immunopharma Shares Rise on Trial UpdateThe company reported no serious adverse events in the early stage of a trial testing its lymphoma therapy.
California biotech reporting spans gene therapy approvals, clinical trial readouts, genomics research with commercial reach, and the financings and acquisitions that move companies from the lab to the market. Coverage reaches from the Bay Area and San Diego corridors to the Central Valley and the smaller research towns around the state. The sector's pace is set as much by capital and manufacturing capacity as by the science itself. Trial results and financing rounds tend to arrive in clusters, so a single data readout often shifts several companies at once.